Sep 29, 2025 • GlobeNewswire
NEUTRAL
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
REDWOOD CITY, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role ...
Sep 11, 2025 • Benzinga
NEUTRAL
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Revolution Medicines ( NASDAQ:RVMD )
In 2L RAS mutant PDAC, daraxonrasib showed 35% ORR and 92% disease control with a median survival of over 13 months. First-line trials showed 47% ORR and 89% disease control, with most patients still on treatment at data cutoff. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Sep 11, 2025 • Benzinga
SOMEWHAT-BULLISH
Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Aon ( NYSE:AON ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Fargo raised W. P. Carey Inc. WPC price target from $68 to $72.
Sep 10, 2025 • GlobeNewswire
NEUTRAL
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability ...
Aug 15, 2025 • Benzinga
SOMEWHAT-BULLISH
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Exodus Movement ( AMEX:EXOD ) , ICU Medical ( NASDAQ:ICUI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo initiated coverage on Revolution Medicines, Inc.